Clinical trial NCT01329666: Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D
Official title: Early Effect of Vitamin D in Primary Hyperparathyroidism
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
PHASE3
Conditions: Primary Hyperparathyroidism
Hypercalcemia
Vitamin D Deficiency
Osteoporosis
Osteopenia
Keywords: Primary Hyperparathyroidism
Endocrinology
Hypercalcemia
Vitamin D deficiency
Parathyroid Hormone
Osteoporosis
Bone Density
Vitamin D repletion
Vitamin D Supplements
Lead sponsor: Columbia University
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2011-04-06
Enrollment: 0
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Primary hyperparathyroidism (PHPT) is a common disease that occurs in 1 in 10,000 people every year. In the presence of this condition, the parathyroid glands produce excessive amounts of parathyroid hormone (PTH), which regulates calcium levels. The high levels of parathyroid hormone remove too much calcium from bones, and then deposit the excess calcium in the blood, which is then filtered into the urine by the kidneys. Bone health is threatened by excess calcium loss which weakens bone structure. Other affected organs include the skeleton (calcium loss leads to a "weakening" of the skeleton), and the kidneys (high blood calcium can lead to kidney stones).

It is now evident that the majority of patients with even mild Primary Hyperparathyroidism are vitamin D deficient. In 2009, new international guidelines for the management of asymptomatic PHPT direct physicians to measure 25-hydroxyvitamin D (D3 or 25-OHD) in all patients, and to replete the reserve of vitamin D when the level is low (\< 20 ng/ml). However, no recommendations for vitamin D repletion are given, because of limited data regarding the effects of vitamin D repletion, appropriate dosing and safety. Therefore, there is an urgent need for data upon which to base such recommendations, as well as are data on the effects of such treatment upon bones.

Subjects with low vitamin D3 levels will be selected for this trial. They will be given enough vitamin D3 to raise their low blood levels from a low to a normal range. The assessments in this study, including the quadruple label bone biopsy, will allow us to document the short term effects of administering vitamin D3 on changes in bone.

All participants enrolled in this trial will be vitamin D3 deficient. Participants will take an antibiotic (tetracycline) 4 times a day to mark the starting point from which bone changes will be assessed. After 3 days of tetracycline, a 12 week course of vitamin D3 or placebo will be initiated. Six of 7 participants will receive the study drug (active vitamin D3), while 1 in 7 will receive a placebo (sugar pill). Ten weeks later, another 3-day course of tetracycline will be given. At the end of 12 weeks, a bone biopsy will be done. A small piece of bone (about the size of a pencil eraser) will be removed from the hip (iliac crest). The bone will be analyzed to determine the effect of vitamin D3 on primary hyperparathyroidism.

There will be 4 study visits: Screening, Baseline, Week 8, and Week 12 when the bone biopsy will be performed.

Study Procedures:

Medical and Social History

Blood tests (drawn at the study center and local Quest Lab)

24-Hour urine collection for calcium and creatinine excretion

Abdominal X-ray (to assess for kidney stones)

Transiliac crest Bone Biopsy


Eligibility criteria: Inclusion Criteria:

1. Females and males \>= 45 years of age
2. PHPT, defined as elevated PTH with elevated serum calcium
3. Screening 25-OHD \<= 20 ng/ml

Exclusion Criteria:

1. Pre-menopausal
2. Serum calcium is \>11.5mg/dl.
3. Urinary calcium is \>350 mg/dl.
4. Active nephrolithiasis
5. Nephocalcinosis
6. Known sensitivity to tetracycline (Sumycin)
7. Familial history of hyperparathyroid syndromes
8. Bisphosphonate use within past 2 years.
9. Current use of Prolia.
10. Current use of Cinacalcet.
11. Currently using Cimetidine.
12. Currently use Colestipol.
13. Currently using Orlistat.
14. Current or past malignancy, except cured basal or squamous cell skin carcinoma or other cancers that have not recurred for at least five years.
15. Current tuberculosis, or history of Sarcoidosis, HIV/AIDS, chronic kidney disease (serum creatinine \>= 1.5), liver disease, Crohn's Disease, Celiac Disease, or gastric bypass

Primary outcomes:
measure: Change in Bone Formation Rate (BFR)
timeFrame: 12 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
Study officials:
affiliation: Columbia University
name: Shonni J. Silverberg, MD
role: PRINCIPAL_INVESTIGATOR
References: